脑曼氏裂头蚴病治疗后的临床结局与抗体水平变化的多中心研究

doi:10.12140/j.issn.1000-7423.2022.02.011

中国寄生虫学与寄生虫病杂志 ›› 2022, Vol. 40 ›› Issue (2): 204-210.doi: 10.12140/j.issn.1000-7423.2022.02.011

脑曼氏裂头蚴病治疗后的临床结局与抗体水平变化的多中心研究

谢慧群¹(), 徐芸¹, 龚志红¹, 胡飞¹, 万慧², 徐春华³, 吴杰⁴, 刘俊朴¹, 洪道俊²^,^*()

1.江西省寄生虫病防治研究所临床部,南昌 330096
2.南昌大学第一附属医院神经内科,南昌 330006
3.南昌大学第一附属医院神经外科,南昌 330006
4.广东三九脑科医院神经外科,广州 510515

收稿日期:2021-07-09 修回日期:2021-08-06 出版日期:2022-04-30 发布日期:2022-04-06
通讯作者: 洪道俊
作者简介:谢慧群（1975-）,女,硕士,副主任医师,从事寄生虫病诊断与治疗。E-mail： huiqunxie@aliyun.com
基金资助:
江西省重点实验室计划(20192BCD40006);江西省科技计划(20151BBG70108)

Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study

XIE Hui-qun¹(), XU Yun¹, GONG Zhi-hong¹, HU Fei¹, WAN Hui², XU Chun-hua³, WU Jie⁴, LIU Jun-pu¹, HONG Dao-jun²^,^*()

1. Clinical Department, Jiangxi Provincial Institute of Parasitic Diseases, Nanchang 330096, China
2. Department of Neurology,the First Affiliated Hospital of Nanchang University,Nanchang 330006, China
3. Department of Neurosurgery,the First Affiliated Hospital of Nanchang University,Nanchang 330006, China
4. Department of Neurosurgery, Guangdong 999 Brain Hospital,Guangzhou 510510, China

Received:2021-07-09 Revised:2021-08-06 Online:2022-04-30 Published:2022-04-06
Contact: HONG Dao-jun
Supported by:
Jiangxi Provincial Key Laboratory Project(20192BCD40006);Jiangxi Province Science and Technology Project(20151BBG70108)

摘要/Abstract

摘要：

目的分析脑曼氏裂头蚴病经临床治疗后的临床结局和血清曼氏裂头蚴抗体IgG滴度变化,以进一步探讨考核该病疗效的指标。方法收集2013—2018年江西省寄生虫病防治研究所、南昌大学第一附属医院、广东三九脑科医院住院及门诊连续治疗随访的脑曼氏裂头蚴病病例。吡喹酮治疗患者给予吡喹酮50 mg/(kg·d),连续给药10 d后,间隔60 d,重复给药3个疗程;手术治疗患者采用开颅手术和CT引导立体定向抽吸术。吡喹酮治疗和手术治疗后12个月,随访患者的临床表现,影像学（头颅MRI平扫及增强）复查,测定曼氏裂头蚴血清IgG抗体水平。采用SPSS 18.0统计学软件进行统计分析。结果共收集87例脑曼氏裂头蚴病病例,其中吡喹酮治疗62例（其中10例吡喹酮治疗后转手术治疗）,手术治疗35例。治疗后12个月,临床结局优的患者有71例,无症状患者占57.7%（41/71）,有临床症状者占42.3%（30/71）,其中抽搐占26.8%（19/71）,轻瘫占14.1%（10/71）,复视占1.4%（1/71）;影像学检查显示,活动性强化病灶消退占85.9%（61/71）,仍有病灶者占14.1%（10/71）,其中单个小结节状病灶的占12.7%（9/71）;血清学检测显示,曼氏裂头蚴血清IgG抗体滴度< 1 ∶ 100（阴性）的患者占64.28%（52/71）,1 ∶ 100的患者占23.80%（12/71）,1 ∶ 200的患者占11.90%（7/71）。治疗后12个月,治疗结局差的患者有16例,无症状者占1/16,有临床症状者占15/16,其中抽搐占12/16,轻瘫占3/16,头痛、病情加重、无明显改善、出现新发症状者各1例;影像学显示,病灶无变化占6/16,病灶增大占1/16,病灶位置变化占7/16,出现新的强化病灶占2/16;血清学检测显示,抗体滴度为1 ∶ 400的患者占4/16,1 ∶ 800的患者占8/16,1 ∶ 1 600的患者占4/16。结论脑曼氏裂头蚴病经吡喹酮和手术治疗后多数预后良好;患者血清学检测可用于考核12个月的近期疗效,可弥补症状和影像学的局限。

关键词: 脑曼氏裂头蚴病, 吡喹酮, 外科手术, 临床结局, 12个月近期疗效

Abstract:

Objective To analyze the clinical outcomes and changes in serum IgG antibody titers against Sparganum mansoni after treatment, for further exploring the indicators in assessing the therapeutic effects for cerebral sparganosis. Methods Cases of cerebral sparganosis patients followed-up on continuous inpatient or outpatient treatment were collected from Jiangxi Provincial Institute of Parasitic Diseases, the First Affiliated Hospital of Nanchang University and Guangdong 999 Brain Hospital during 2013 to 2018. The patients were administrated with praziquantel 50 mg/(kg·d) for 10 days per cource, continuing for three cources at a 60-day interval. The surgical treatment includes craniotomy and CT-guided stereotactic aspiration. Twelve months after the treatment with praziquantel and surgery, the clinical manifestations of patients were followed-up, imaging examination (including brain MRI flat and enhanced scan) rechecked, and the serum IgG titer assayed. Statistical analysis was performed using SPSS 18.0 software. Results Eighty-seven cases of cerebral sparganosis were collected, of which 62 patients received praziquantel treatment (10 patients were treated with praziquantel prior to surgery), and 35 patients underwent surgical therapy. After 12 months of treatment, among the 71 patients with good outcomes, 57.7% (41/71) were asymptomatic, 42.3% (30/71) had clinical symptoms, among them 26.8% (19/71) with seizure, 14.1% (10/71) with paresis, and 1.4% (1/71) with diplopia. Radiography showed that 85.9% (61/71) of active enhanced foci were resolving, while 14.1% (10/71) foci remained, of them 12.7% (9/71) were single small nodular lesions. Serology examination revealed that 64.28% (52/71) cases were negative for IgG against Sparganum mansoni (antibody titer < 1 ∶ 100), 23.80% (12/71) had an antibody titer of 1 ∶ 100, and 11.90% (7/71) had the titer of 1 ∶ 200. After treatment for 12 months, 16 patients were of poor outcomes, showing 1/16 was free of symptom, and 15 had clinical symptoms, of them 12/16 patients with seizure, 3/16 with paresis, while headache, aggravating illness, no significant improvement and emerging new symptoms were found of 1 case each. Radiography indicated that among the cases, 6/16 showed no changes in lesion images, 1/16 had enlarged foci, 7/16 changes in lesion location, and 2/16 newly enhanced lesions. Serology examination on the patients showed 4/16 had an antibody titer of 1 ∶ 400, 8/16 had the titer of 1 ∶ 800 and 4/16 had the titer of 1 ∶ 1 600. Conclusion Most of the cerebral sparganosis cases had a good prognosis after praziquantel and surgery treatment. Serological tests could be used for assessment of recent therapeutic effect in 12 months, redeeming the limitations in appraisal by symptoms and imaging.

Key words: Cerebral sparganosis, Praziquantel, Surgery, Clinical outcome, 12-months short-term efficacy

中图分类号:

R532.31

谢慧群, 徐芸, 龚志红, 胡飞, 万慧, 徐春华, 吴杰, 刘俊朴, 洪道俊. 脑曼氏裂头蚴病治疗后的临床结局与抗体水平变化的多中心研究[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(2): 204-210.

XIE Hui-qun, XU Yun, GONG Zhi-hong, HU Fei, WAN Hui, XU Chun-hua, WU Jie, LIU Jun-pu, HONG Dao-jun. Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2022, 40(2): 204-210.

图/表 3

表1

图1

图2

参考文献 29

[1]	Xu Y,, Wan H,, Hong DJ, et al. Cerebral clinical features and outcome of 123 patients with sparganosis[J]. Jiangxi Med J, 2017, 52(4): 286-289. (in Chinese)
[1]	(徐芸,, 万慧,, 洪道俊, 等. 123例曼氏裂头蚴病的临床特点及治疗观察[J]. 江西医药, 2017, 52(4): 286-289.)
[2]	Yan XQ,, Li XL,, Sun ZQ, et al. Clinical features of 83 cases of cerebral sparganosis[J]. Chin J Parasitol Parasit Dis, 2021, 39(2): 240-245. (in Chinese)
[2]	(闫学强,, 李晓龙,, 孙祯卿, 等. 83例脑裂头蚴病患者临床资料分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 240-245.)
[3]	Kim JG,, Ahn CS,, Sohn WM, et al. Human sparganosis in Korea[J]. J Korean Med Sci, 2018, 33(44): e273.
[4]	Lo Presti A,, Aguirre DT, et al. Cerebral sparganosis: case report and review of the European cases[J]. Acta Neurochir (Wien), 2015, 157(8): 1339-1343.
[5]	Zeng QR,, He M,, Wang F, et al. Pathogen identification of 10 suspected cases of sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2012, 30(3): 224-227, 232. (in Chinese)
[5]	(曾庆仁,, 贺美,, 王芳, 等. 10例疑似曼氏裂头蚴病的病原学诊断[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(3): 224-227, 232.)
[6]	Meng YM,, Kuang ZW,, Liao L, et al. Case report: morphologic and genetic identification of cerebral sparganosis[J]. Am J Trop Med Hyg, 2019, 101(5): 1174-1176.
[7]	Zhu YL,, Ye LQ,, Ding XS, et al. Cerebral sparganosis presenting with atypical postcontrast magnetic resonance imaging findings: a case report and literature review[J]. BMC Infect Dis, 2019, 19(1): 748.
[8]	Zhang P,, Zou Y,, Yu FX, et al. Follow-up study of high-dose praziquantel therapy for cerebral sparganosis[J]. PLoS Negl Trop Dis, 2019, 13(1): e0007018.
[9]	Hong DJ,, Xie HQ,, Wan H, et al. Efficacy comparison between long-term high-dose praziquantel and surgical therapy for cerebral sparganosis: a multicenter retrospective cohort study[J]. PLoS Negl Trop Dis, 2018, 12(10): e0006918.
[10]	Gonzenbach RR,, Kong Y,, Beck B, et al. High-dose praziquantel therapy for cerebral sparganosis[J]. J Neurol, 2013, 260(5): 1423-1425.
[11]	Xie HQ,, Long Y,, Xu Y, et al. Clinical features, radiological characteristics and pathological changes in 42 patients with cerebral sparganosis[J]. Chin J Neurol, 2015, 48(2): 108-113. (in Chinese)
[11]	(谢慧群,, 龙勇,, 徐芸, 等. 脑曼氏裂头蚴病患者42例的临床、影像与病理特点分析[J]. 中华神经科杂志, 2015, 48(2): 108-113.)
[12]	Hong DJ,, Xie HQ,, Zhu M, et al. Cerebral sparganosis in mainland Chinese patients[J]. J Clin Neurosci, 2013, 20(11): 1514-1519.
[13]	Chen XH,, Shi GF. Clinical analysis of 6 cases with cerebral sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2010, 28(5): 397-398. (in Chinese)
[13]	(陈先汉,, 施光峰. 脑曼氏裂头蚴病6例临床分析[J]. 中国寄生虫学与寄生虫病杂志, 2010, 28(5): 397-398.)
[14]	Ye SK,, Xu L,, Huang Q, et al. The epidemiology, clinical feature, radiology and outcome of 8 cases with cerebral sparganosis mansoni[J]. Chin J Parasitol Parasit Dis, 2018, 36(2): 144-147. (in Chinese)
[14]	(叶善可,, 徐烈,, 黄琴, 等. 8例脑曼氏裂头蚴病的流行病学特点、临床特征、影像学表现与预后分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 144-147.)
[15]	Kim YB,, Hw ang SN,, Cho SY, et al. Cereberal spargnosis: two cases diagnosed by CT/MR and ELISA tests[J]. J Korean Neurosurg Soc, 1993, 22(6): 585-590.
[16]	Choi SH,, Kang SY,, Kong Y, et al. Antigenic protein fractions reacting with sera of sparganosis patients[J]. Kisaengchunghak Chapchi, 1988, 26(3): 163-167.
[17]	Hwang JM,, Hwang DS,, Kang C, et al. Subcutaneous sparganosis mimicking soft tissue tumor: a case report[J]. Int Med Case Rep J, 2019, 12: 47-50.
[18]	National Health and Family Planning Commission. Diagnosis of sparganosis WS 438-2013[S]. Beijing: Standards Press of China, 2013. (in Chinese)
[18]	国家卫生和计划生育委员会. 裂头蚴病的诊断 WS 438-2013[S]. 北京: 中国标准出版社, 2013.
[19]	Wang P,, Su XY,, Mao Q, et al. The surgical removal of a live tapeworm with an interesting pathologic finding most likely representing the migration path: a case report of cerebral sparganosis[J]. Clinics (Sao Paulo), 2012, 67(7): 849-851.
[20]	Chu SG,, Lu XS,, Wang Y, et al. Magnetic resonance imaging features of pathologically proven cerebral sparganosis[J]. J Int Med Res, 2013, 41(3): 867-877.
[21]	Shirakawa K,, Yamasaki H,, Ito A, et al. Cerebral sparganosis: the wandering lesion[J]. Neurology, 2010, 74(2): 180.
[22]	Torres JR,, Noya OO,, Noya BA, et al. Treatment of proliferative sparganosis with mebendazole and praziquantel[J]. Trans R Soc Trop Med Hyg, 1981, 75(6): 846-847.
[23]	Deng L,, Xiong PJ,, Qian SK. Diagnosis and stereotactic aspiration treatment of cerebral sparganosis: summary of 11 cases[J]. J Neurosurg, 2011, 114(5): 1421-1425.
[24]	Sohn WM,, Hong ST,, Chai JY, et al. Infectivity of the Sparganum treated by praziquantel, gamma-irradiation and mechanical cutting[J]. Korean J Parasitol, 1993, 31(2): 135-139.
[25]	Chan JD,, Zarowiecki M,, Marchant JS. Ca²⁺ channels and praziquantel: a view from the free world[J]. Parasitol Int, 2013, 62(6): 619-628.
[26]	Andrews P,, Thomas H,, Pohlke R, et al. Praziquantel[J]. Med Res Rev, 1983, 3(2): 147-200.
[27]	Gonzenbach RR,, Kong Y,, Beck B, et al. High-dose praziquantel therapy for cerebral sparganosis[J]. J Neurol, 2013, 260(5): 1423-1425.
[28]	Doenhoff MJ,, Cioli D,, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis[J]. Curr Opin Infect Dis, 2008, 21(6): 659-667.
[29]	Kim DG,, Paek SH,, Chang KH, et al. Cerebral sparganosis: clinical manifestations, treatment, and outcome[J]. J Neurosurg, 1996, 85(6): 1066-1071.

中心名称 Center	病例数 No. case	治疗例数 No. case
中心名称 Center	病例数 No. case	吡喹酮 Praziquantel	外科 Surgey
江西省寄生虫病防治研究所Jiangxi Provincial Institute of Parasitic Diseases	52 - 6^a	52 - 6^a	0
南昌大学第一附属医院 First Affiliated Hospital of Nanchang University	31	10 - 4^a	21 + 4^a
广东三九脑科医院 Guangdong 999 Brain Hospital	4 + 6^a	0	4 + 6^a
合计Total	87	62 - 10^a	35

脑曼氏裂头蚴病治疗后的临床结局与抗体水平变化的多中心研究

Clinical outcome and change of antibody level in cerebral sparganosis mansoni patients after treatment: a multicenter study

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	欧阳兵, 李仁喜. 食生三文鱼致感染阔节双叶槽绦虫1例[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(3): 295-298.
[2]	黄燕, 喻文杰, 尚婧晔, 何伟, 张光葭, 王奇, 杨柳, 廖沙, 李汭芮, 姚人新, 曾明才, 张福斌, 李树成, 刘阳, 钟波, 王谦. 阿苯达唑和吡喹酮交替联合用药治疗藏族牧民棘球蚴病的效果观察[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 171-177.
[3]	赵成思, 秦敏, 谭明娟, 缪婷婷, 邵天业, 刘新建, 王勇. 吡喹酮对日本血吸虫急性感染小鼠肾脏功能损伤的影响[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 200-209.
[4]	闫学强, 李晓龙, 孙祯卿, 吴杰. 83例脑裂头蚴病患者临床资料分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(2): 240-244.
[5]	王伟, 赵成思, 缪婷婷, 周春雷, 张成诚, 秦敏, 邵天业, 王勇. 吡喹酮治疗对日本血吸虫感染小鼠脾巨噬细胞增殖和炎症反应的抑制作用[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(3): 263-270.
[6]	赵晋英, 刘鹏, 李艳伟, 汪世平. 血吸虫病联合用药的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2020, 38(3): 370-377.
[7]	叶善可, 徐烈, 黄琴, 凌云. 8例脑曼氏裂头蚴病的流行病学特点、临床特征、影像学表现与预后分析[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(2): 144-147.
[8]	张玉梅1,2，王燕娟1 *，刘华1，姜岩岩1，徐馀信1，郑力1,3，胡媛1，沈玉娟1，曹建平1. 吡喹酮治疗后日本血吸虫感染小鼠滤泡辅助性T细胞及其表面分子的研究[J]. 中国寄生虫学与寄生虫病杂志, 2016, 34(2): 2-99-104.
[9]	宋国平，李金福，陈艳*，徐婧. 雷丸及吡喹酮对猬迭宫绦虫裂头蚴感染性及超微结构的影响[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(1): 8-40-44.
[10]	刘向芹1,2，田喜凤1，张瑾2，辛晓芳2，张影2 *. 吡喹酮治疗血吸虫感染小鼠后IFN-γ和IL-4及T细胞的变化[J]. 中国寄生虫学与寄生虫病杂志, 2014, 32(2): 5-106-109.
[11]	肖树华, 薛剑. 甲氟喹抗血吸虫及其他蠕虫作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(2): 10-131-138,145.
[12]	徐莉莉, 薛剑, 张永年, 强慧琴, 肖树华*. 7种抗蠕虫药物的体外抗华支睾吸虫作用[J]. 中国寄生虫学与寄生虫病杂志, 2011, 29(1): 3-10-15.
[13]	薛剑;徐莉莉;强慧琴;张永年;肖树华. 用三苯双脒、吡喹酮和青蒿琥酯临床给药方案治疗感染华支睾吸虫大鼠的研究[J]. 中国寄生虫学与寄生虫病杂志, 2010, 28(3): 2-171.
[14]	肖树华. 近年来发展抗血吸虫新药的进展[J]. 中国寄生虫学与寄生虫病杂志, 2010, 28(3): 13-225.
[15]	黎淑娟;欧强;施裕新. 脑曼氏裂头蚴病1例[J]. 中国寄生虫学与寄生虫病杂志, 2010, 28(1): 23-53.